Search Results - "Sandgaard, Susanne"

The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease by Ehlers, Lars Holger, Lamotte, Mark, Monteiro, Sofia, Sandgaard, Susanne, Holmgaard, Pia, Frary, Evan C., Ejskjaer, Niels

“…Introduction The increasing financial burden associated with diabetes treatment presents a challenge to healthcare systems worldwide. Recently, clinical…”
Get full text

The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark by Ehlers, Lars H., Lamotte, Mark, Ramos, Mafalda C., Sandgaard, Susanne, Holmgaard, Pia, Kristensen, Malene M., Ejskjaer, Niels

“…Introduction International and Danish guidelines recommend the use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium–glucose cotransporter 2…”
Get full text

The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark by Ehlers, Lars H, Lamotte, Mark, Ramos, Mafalda C, Sandgaard, Susanne, Holmgaard, Pia, Frary, Evan C, Ejskjaer, Niels

“…To evaluate the cost–effectiveness of oral semaglutide+metformin versus empagliflozin+metformin in people with Type 2 diabetes uncontrolled on msetformin…”
Get full text

Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark by Thomsen, Reimar W., Christensen, Lotte W. B., Kahlert, Johnny, Knudsen, Jakob S., Ustyugova, Anastasia, Sandgaard, Susanne, Holmgaard, Pia, Ehlers, Lars H., Sørensen, Henrik T.

“…Introduction The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin has shown reductions in major adverse cardiac events similar to glucagon-like…”
Get full text